Real-time · AI · Cross-signal
NewAmsterdam Pharma Company N.V just moved. Here's exactly what to do next.
Who to reach, what to say, and why now — on NewAmsterdam Pharma Company N.V, plus every contract, funding round, and exec hire that follows. Verified, ICP-ranked contacts on demand (email + mobile).
Used by professionals at BlackRock, Oracle, Kleiner Perkins, HubSpot, and other leading firms — built on 10 years of proprietary signal data.
NewAmsterdam Pharma Announces Closing of Upsized Public Offering of Ordinary Shares and Pre-Funded Warrants
Dec 13, 2024•over 1 year ago
Contract Type
partnership
BiotechnologyHealth CareTherapeuticsPharmaceuticalBiopharma
Description
NewAmsterdam Pharma Company N.V. announced the closing of an underwritten public offering of ordinary shares and pre-funded warrants. The net proceeds to the company from the offering were approximately $452.6 million after deducting underwriting discounts and commissions and estimated offering expenses payable by the Company.
Agreement Insights
Based on industry dataStrategic partnership established
Partnership agreements typically involve technology integration and joint go-to-market strategies
Contract momentum indicator
Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months